

1 **Induction of an early IFN- $\gamma$  cellular response and high plasma levels of SDF-1 $\alpha$  are**  
2 **inversely associated with COVID-19 severity and residence in rural areas in Kenyan**  
3 **patients**

4 **Short Title:** Early IFN- $\gamma$  response and high SDF-1 $\alpha$  levels linked to Lower COVID-19  
5 Severity in rural Kenyan patients

6 **Authors**

7 Perpetual Wanjiku <sup>1\*</sup>, Benedict Orindi <sup>1</sup>, John Kimotho <sup>1</sup>, Shahin Sayed <sup>2</sup>, Reena Shah <sup>2</sup>,  
8 Mansoor Saleh <sup>2</sup>, Jedidah Mwacharo <sup>1</sup>, Christopher Maronga <sup>3</sup>, Vivianne Olouch <sup>2</sup>, Ann  
9 Karanu <sup>2</sup>, Jasmit Shah <sup>4</sup>, Zaitun Nneka <sup>2</sup>, Lynette Isabella Ochola-Oyier <sup>1 5</sup>, Abdirahman I.  
10 Abdi <sup>1 5</sup>, Susanna Dunachie <sup>6</sup>, Philip Bejon <sup>1 5</sup>, Eunice Nduati <sup>1 5</sup>, Francis M. Ndungu <sup>1 5\*</sup>.

11 **Affiliations**

12 <sup>1</sup> Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute  
13 (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.

14 <sup>2</sup> Aga Khan University Hospital, 3rd Parklands Avenue, Nairobi, Kenya.

15 <sup>3</sup> Nuffield Department of Population Health, Cancer Epidemiology Unit, University of  
16 Oxford, Oxford, United Kingdom.

17 <sup>4</sup> Brain and Mind Institute and Department of Medicine, Aga Khan University, Nairobi,  
18 Kenya.

19 <sup>5</sup> Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

20 <sup>6</sup> Nuffield Department of Medicine, Centre for Global Health Research, University of  
21 Oxford, Oxford, United Kingdom.

22

23 \* Corresponding authors

24 [pwanjiku@kemri-wellcome.org](mailto:pwanjiku@kemri-wellcome.org) (PW)

25 [fdungu@kemri-wellcome.org](mailto:fdungu@kemri-wellcome.org) (FMN)

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 26 **Abstract**

### 27 **Introduction**

28 COVID-19 was less severe in Sub-Saharan Africa (SSA) compared with Europe and North  
29 America. It is unclear whether these differences could be explained immunologically. Here  
30 we determined the levels of *ex vivo* SARS-CoV-2 peptide-specific IFN- $\gamma$  producing cells, and  
31 levels of plasma cytokines and chemokines over the first month of COVID-19 diagnosis  
32 among Kenyan COVID-19 patients from urban and rural areas.

### 33 **Methods**

34 Between June 2020 and August 2022, we recruited and longitudinally monitored 188  
35 COVID-19 patients from two regions in Kenya, Nairobi (urban, n = 152) and Kilifi (rural, n =  
36 36), with varying levels of disease severity – severe, mild/moderate, and asymptomatic. IFN-  
37  $\gamma$  secreting cells were enumerated at 0-, 7-, 14- and 28-days post diagnosis by an *ex vivo*  
38 enzyme-linked immunospot (ELISpot) assay following *in vitro* stimulation of peripheral  
39 blood mononuclear cells (PBMCs) with overlapping peptides from several SARS-CoV-2  
40 proteins. A multiplexed binding assay was used to measure the levels of 22 plasma cytokines  
41 and chemokines.

### 42 **Results**

43 Higher frequencies of IFN- $\gamma$ -secreting cells against the SARS-CoV-2 spike peptides were  
44 observed on the day of diagnosis among the asymptomatic compared to the patients with  
45 severe COVID-19. Higher concentrations of 17 of the 22 cytokines and chemokines  
46 measured were positively associated with severe disease, and in particular interleukin (IL)-8,  
47 IL-18 and IL-1ra ( $p < 0.0001$ ), while a lower concentration of SDF-1 $\alpha$  was associated with  
48 severe disease ( $p < 0.0001$ ). Concentrations of 8 and 16 cytokines and chemokines including  
49 IL-18 were higher among Nairobi asymptomatic and mild patients compared to their

50 respective Kilifi counterparts. Conversely, the concentrations for SDF-1 $\alpha$  were higher in rural  
51 Kilifi compared to Nairobi (p=0.012).

## 52 **Conclusion**

53 In Kenya, as seen elsewhere, pro-inflammatory cytokines and chemokines were associated  
54 with severe COVID-19, while an early IFN- $\gamma$  cellular response to overlapping SARS-CoV-2  
55 spike peptides was associated with reduced risk of disease. Living in urban Nairobi  
56 (compared with rural Kilifi) was associated with increased levels of pro-inflammatory  
57 cytokines/chemokines.

58 **Keywords:** COVID-19, SARS-CoV-2, IFN- $\gamma$ -secreting cells, cytokines, chemokines,  
59 kinetics, Sub-Saharan Africa.

## 61 **Introduction**

62 Despite widespread transmission of SARS-CoV 2, SSA experienced a reduced burden of  
63 severe coronavirus disease 2019 (COVID-19) and associated mortality than North America  
64 and Europe (1). This observation is both puzzling (2) and paradoxical (3), because of the  
65 relatively weaker and underfunded health systems in SSA. Some of the proposed, but still  
66 unproven, explanations for the reduced burden of severe COVID-19 in SSA include under-  
67 diagnosis of cases and mortality, a younger population (7), warmer climatic conditions with  
68 outdoor living, high levels of pre-existing cross-protective antibodies and T-cells induced  
69 from a high prevalence of infectious agents with SARS-CoV-2 like immune determinants,  
70 and immune regulation associated with either prior BCG vaccination (5–11) or  
71 chronic/repeated infections including helminths (12) and malaria (13). Like other viruses,  
72 SARS-CoV-2 induces a plethora of inflammatory host responses, including cytokines and  
73 chemokines (14), that play key roles in either protective immunity or immunopathology (15).  
74 Notably, the pathogenesis of COVID-19 has been linked to dysregulated and excessive  
75 cytokine and chemokine responses, upon SARS-CoV-2 infection (16). Numerous studies  
76 have linked increased levels of cytokines and chemokines to severe COVID-19 and  
77 associated mortality, including IL-1 $\beta$ , IL-1ra, IL-2, IL-6, IL7, IL-8, IL-18, IFN- $\gamma$ , TNF- $\alpha$ ,  
78 IFN- $\gamma$ -inducible protein 10 (IP-10), granulocyte macrophage-colony stimulating factor (GM-  
79 CSF), monocyte chemoattractant protein-1 (MCP-1), and Macrophage inflammatory protein-  
80 1 alpha (MIP-1- $\alpha$ ) (17–24). Collectively called a “cytokine storm”, a dysregulated cytokine  
81 response is implicated as the cause of the multiple organ failures and the acute respiratory  
82 distress syndrome (ARDS), which characterise severe COVID-19 and associated fatalities  
83 (25).

84 Published data show that the characteristic antibody response to SARS-CoV-2 infection,  
85 where levels increase with time, viral loads and COVID-19 severity, were experienced in  
86 Kenyan patients (26). Thus, there is no evidence of the primary acute antibody response  
87 controlling the infection outcome. Aside from antibodies, T-cell responses can control  
88 viremia, either directly by killing virus infected cells or indirectly by providing the relevant  
89 co-stimulatory molecules for supporting antibody production by B cells (27). However, there  
90 is a paucity of data on the cellular response to SARS-CoV-2 in Kenyan patients, and its  
91 possible role in modulating disease severity. Furthermore, it is unclear whether the  
92 differences in the rates of severe disease between urban and rural dwellers within SSA, as  
93 well as between developed countries and SSA, could be explained immunologically. In this  
94 study, we collected longitudinal blood samples from individuals from Nairobi (urban) and  
95 Kilifi (rural) with varying degrees of COVID-19 severity (asymptomatic, mild/moderate and  
96 severe) and compared levels of their *ex vivo* SARS-CoV-2 Spike peptide-specific IFN- $\gamma$   
97 producing cells, and levels of plasma cytokines and chemokines over their first month of  
98 COVID-19 diagnosis.

99

## 100 **Methods**

### 101 **Study design, setting and participants**

102 Participant sampling has been described previously (26). Briefly, we included 400 blood  
103 samples from a longitudinal cohort study of 188 patients that aimed at understanding the  
104 kinetics of naturally acquired immune responses to SARS-CoV-2 among COVID-19 patients  
105 from two sites in Kenya: 1) The Aga Khan University Hospital (AKUH) in Nairobi, an urban  
106 metropolitan academic medical Centre; and 2) Kilifi County Hospital, a community-based  
107 government hospital serving a rural coastal region. The samples were collected during the  
108 COVID-19 pandemic between June 2020 and August 2022. At the time of the study, SARS-  
109 CoV-2 transmission in Nairobi was higher than in Kilifi (28). Participants were adults, aged  
110  $\geq 18$  years old, recruited within seven days of positive diagnosis of COVID-19 by RT-PCR  
111 testing. Initial sampling was at day 0 (i.e., day of diagnosis). Follow-up and subsequent  
112 samplings were done on days 7, 14 and 28 from a positive SARS-CoV-2 infection diagnosis.  
113 We collected 20 mL of venous blood in sodium heparin vacutainer. Additionally, we  
114 included residual longitudinal plasma samples from the AKUH biobank for cytokine and  
115 chemokine measurements. These samples were collected from COVID-19 patients who  
116 consented to this follow-up study on the day of diagnosis (i.e., day 0) and on day 28.

### 117 **COVID-19 severity classification**

118 We included patients from five COVID-19 severity groups of asymptomatic, mild, moderate,  
119 severe, and critical as determined by clinicians at the time of diagnosis following the  
120 National Institutes of Health (NIH, USA) guidelines(29). Asymptomatic patients were those  
121 who tested positive for SARS-CoV-2 via RT-PCR but did not display any COVID-19  
122 symptoms. Mild cases were SARS-CoV-2 positive and exhibited symptoms such as fever,  
123 sore throat, cough, malaise, headache, muscle pain, vomiting, nausea, diarrhoea, anosmia, or

124 ageusia, without any signs of shortness of breath, dyspnea, or abnormal chest imaging.  
125 Moderate cases tested positive for SARS-CoV-2 and showed evidence of lower respiratory  
126 tract infection based on clinical examination or imaging, with an oxygen saturation (SpO<sub>2</sub>) of  
127  $\geq 94\%$  on room air. Severe cases were positive for SARS-CoV-2 with an SpO<sub>2</sub> of  $< 94\%$  on  
128 room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen  
129 (PaO<sub>2</sub>/FiO<sub>2</sub>)  $< 300$  mm Hg, a respiratory rate  $> 30$  breaths/minute, and/or lung infiltrates  
130  $> 50\%$ . Critically ill patients were positive for SARS-CoV-2 and experienced respiratory  
131 failure, septic shock, and/or multiple organ dysfunction syndrome. Due to the small numbers  
132 in the moderate and critical groups, mild cases were lumped together with moderate  
133 (mild/moderate), whilst critical were grouped with severe ones (severe). Thus, we studied  
134 immune responses among three COVID-19 patient groups: asymptomatic, mild/moderate and  
135 severe.

## 136 **Procedures**

### 137 **Plasma separation and PBMC isolation**

138 Plasma was separated by centrifuging the tubes at 440 g for 10 minutes using an Eppendorf  
139 5810R centrifuge, aliquoted in 2 mL microcentrifuge tubes, and immediately stored in  $-80^{\circ}\text{C}$   
140 freezers until the time for laboratory analysis. PBMCs were isolated from the remaining  
141 blood component using density gradient centrifugation media (Lymphoprep<sup>TM</sup> (1.077 g/ml,  
142 Stem Cell Technologies), aliquoted to 1.8 mL cryovials, and stored in  $-196^{\circ}\text{C}$  liquid nitrogen  
143 tanks until usage. Plasma and PBMC samples from AKUH were transported in dry ice and  
144 liquid nitrogen respectively, to the KEMRI–Wellcome Trust Research Programme  
145 laboratories in Kilifi and stored appropriately for laboratory analyses. Prior to use, PBMCs  
146 were thawed and rested at  $37^{\circ}\text{C}$ , 5% CO<sub>2</sub> for 15–16 hours. PBMC counting was done using  
147 Vi-CELL XR Cell Viability Analyser or Countess<sup>TM</sup> Cell Counting Chamber Slides (Thermo  
148 Scientific) before assay setup.

## 149 **SARS-CoV-2 synthetic peptides pools for ELISpot measurements**

150 A total of 641 peptides (15–18-mers with a ten amino acid overlap) were pooled into ten  
151 peptide pools, spanning different regions of the virus. The pools covered: the spike protein  
152 region (S1: positions 1–93 and S2: positions 94–178), membrane protein (M: positions 1–31),  
153 nucleocapsid protein (NP: positions 1–55), non-structural proteins (NSP 3B: positions 207–  
154 306, NSP 3C: position 307–379, NSP 12B: positions 665–729 and NSP 15–16: positions 886–  
155 972) and Open Reading Frame (ORF3: positions 1–37 and ORF8: positions 1–15). These  
156 peptides (which were synthesised by Mimotopes Pty Ltd and a kind donation from Professor  
157 Susanna Dunachie’s laboratory, Oxford University) were used to stimulate PBMCs for *ex*  
158 *vivo* IFN- $\gamma$  ELISpot assay. The peptide sequences and pooling details are provided in Table  
159 S1.

## 160 **Interferon gamma ELISpot assay**

161 To quantify *the ex vivo* interferon gamma (IFN- $\gamma$ ) cellular response to overlapping SARS-  
162 CoV-2 peptides from different proteins, we stimulated PBMC with synthetic peptides pools  
163 through an *in vitro* IFN- $\gamma$  ELISpot assay, as previously described (30). Briefly, 5  $\mu\text{g/ml}$  of  
164 anti- human IFN- $\gamma$  antibody clone 1-D1K (Mabtech, AB, Sweden) was used to coat  
165 Multiscreen-I 96 ELISpot plates overnight. Individual’s PBMC were plated in duplicates at  
166 200,000 cells per well for each specific protein, based on pre-prepared plate templates.  
167 Peptide pools were then added at a final concentration of 2  $\mu\text{g/mL}$  per wells and incubated  
168 for 16–18 hours at 37°C, 5% CO<sub>2</sub>, 95% humidity. Concanavalin A (ConA; Sigma) was used  
169 as the positive control at a final concentration of 5  $\mu\text{g/mL}$  per well, while dimethyl sulfoxide  
170 (DMSO; Sigma), which was a constituent of the diluent for the peptides and Con A was used  
171 at a similar concentration to peptides to serve as the negative control. IFN- $\gamma$  secreting cells  
172 were then detected using an anti-human IFN- $\gamma$  biotinylated antibody clone 7-B6-1 (Mabtech)  
173 at 1  $\mu\text{g/mL}$  and an incubation for 2–4 hours. Thereafter, streptavidin alkaline phosphatase



174 antibody (Mabtech) was added at 1  $\mu\text{g}/\text{mL}$  and incubated for 1–2 hours, and the IFN- $\gamma$  spots  
175 then developed using 1-Step™ NBT/BCI (nitro blue tetrazolium/5-bromo-4-chloro-3-  
176 phosphatase) substrate (Thermo Scientific) during a 7-minute incubation in the dark. The  
177 enzyme-substrate reaction was stopped by rinsing the plate 3 times under running tap water.  
178 Plates were then airdried for at least 2 days on an open lab bench, and spots enumerated on an  
179 AID ELISpot Reader version 4.0. Results are hereby reported as spot-forming units  
180 (SFU)/ $10^6$  PBMC after subtracting the background (mean SFU from negative control  
181 wells). Data from failed individual PBMC tests, defined here as either, an excessive  
182 background where the negative control wells had  $>80$  SFU/ $10^6$  PBMCs, or a positive  
183 control well with an average of  $<100$  SFU/ $10^6$  PBMCs (too few), were excluded. We also  
184 applied the ELISpot assay limit of detection of 10 SFU/ $10^6$  PBMCs, with all wells having  
185 values  $<10$  SFU/ $10^6$  PBMCs replaced with 5 SFU/ $10^6$  PBMCs. For the participants who  
186 did not have enough PBMC to be tested against all the peptide pools, we prioritised  
187 measurements against pools from S1, S2, NP and M proteins. Data are reported only for the  
188 individuals whose PBMC were tested against all the available peptide pools for each specific  
189 protein segment. We summed the responses from the different pools of the same protein  
190 segment, which resulted in different sample sizes for different proteins as follows: spike (171  
191 samples for S1, S2), NP (162 samples), M (136 samples), NSPs (100 samples for NSP 3B,  
192 NSP 3C, NSP 12B and NSP 15 -16) and ORF (90 samples for ORF 3 and ORF 8) Table S2.

### 193 **Luminex assay**

194 Plasma concentrations of 22 cytokines and chemokines were measured using a Human  
195 ProcartaPlex™ Human Panel 1A (Thermo Fisher Scientific, Cat. No. EPX010-12010-901,  
196 Lot number 316776-000), which consisted of: a) Th1/Th2 specific cytokines: GM-CSF, IFN-  
197  $\gamma$ , IL-1 $\beta$ , IL-2, IL-6, IL-8, IL-18, TNF- $\alpha$ , IL-9, IL-21; b) Pro-Inflammatory cytokines: IFN- $\alpha$ ,  
198 IL-1 $\alpha$ , IL-1ra, IL-7, TNF- $\beta$ ; and c) Chemokines: Eotaxin, GRO- $\alpha$ , IP-10, MCP-1, MIP-1 $\alpha$ ,

199 MIP-1 $\beta$ , SDF-1 $\alpha$ , according to the manufacturer's instructions. Briefly, 1x capture magnetic  
200 beads were added to the plates, and unbound beads were then washed away with 1X wash  
201 buffer. Plasma samples were thawed and diluted at 1:2 with 1X universal assay buffer (UAB)  
202 before addition to the plates. Standards from the kit at 4-fold serial dilutions of 1:5, 1:20,  
203 1:80, 1:320, 1:1280, 1:5120, 1:20480 as well as a blank (UAB), were also added. The plates  
204 were then incubated on a shaker at 600 rpm for 2 hours at room temperature. After  
205 incubation, contents were discarded, plates washed, and 1X biotinylated detection antibody  
206 added. The plates were then incubated for 30 minutes on an Eppendorf Thermomixer  
207 Comfort shaker at room temperature. The plates were then washed, and 1X Streptavidin-PE  
208 added and incubated for 30 minutes on an Eppendorf Thermomixer Comfort shaker at room  
209 temperature, the plates were then washed before adding 1X reading buffer for 5 minutes on  
210 an Eppendorf Thermomixer Comfort shaker at room temperature. All wash steps were  
211 performed on an Invitrogen hand-held magnetic plate washer. Data were acquired on the  
212 Magpix systems multiplex Luminex machine and concentrations (pg/mL) of the samples  
213 calculated in Belysa® Immunoassay Curve Fitting software version 1.1.0 (31) using a 5- or  
214 4-parameter logistic standard curve generated from standards of known concentration.

## 215 **Statistical analysis**

216 For the ELISpot data, time point specific geometric means (GMs) of IFN- $\gamma$  secreting cells for  
217 each of the different SARS-COV-2 peptides pools were calculated for each severity group  
218 and geographical location. For each peptide, variations in ELISpot responses were compared  
219 using a linear mixed effects model on log-transformed PBMCs values with patient as a  
220 random effect, and time (i.e., day of sampling), severity group and time-by-severity group  
221 interaction term as fixed effects (32), followed by Tukey's multiple comparisons. Within  
222 each severity group, differences between geographic locations were compared using Kruskal

223 Wallis paired with a Dunn's multiple comparisons. This analysis set was restricted to 59  
224 patients who had PBMC samples.

225 Cytokine and chemokine data were first normalised to have a zero mean and a standard  
226 deviation of one, and cross-correlations among the cytokines determined using Pearson  
227 correlations and principal component analysis (PCA). Principal components (PCs) were  
228 extracted based on scree-plot, variance explained and the interpretability of the components.

229 Next, the non-normalised cytokine and chemokine data were log-transformed and fitted into  
230 linear mixed effects regression models with age, sex, day of sampling, location or disease  
231 severity as fixed effects and patient as a random effect. Interactions were explored and  
232 separate models fitted where necessary. For location comparisons, severe and moderate  
233 COVID-19 cases were excluded as these categories were only present in the Nairobi data.

234 Results from the regression models were presented using heat maps, in which the effect size  
235 (i.e., coefficient) determined the density of colour-shading for each square. TNF- $\beta$  data were  
236 excluded from the analyses as only one patient had a measurable concentration. Thus, we  
237 analysed 21 cytokines from all 188 patients. Analyses were performed using R version 4.3.0  
238 (33). The factoextra package (34) was used for PCA. For visualisations, the pheatmap (35)  
239 and ggplot2 (36) packages and GraphPad Prism Software version 10.1.2 (37) were used.

## 240 **Ethical approval**

241 The study obtained ethical approval from the Kenya Medical Research Institute's Scientific  
242 and Ethics Review Unit (KEMRI SERU; protocol no. 4081) and the Aga Khan University,  
243 Nairobi, Institutional Ethics Review Committee (protocol no. 2020 IERC-135 V2). Written  
244 informed consent was obtained from all willing patients before their enrolment into the study.

245

## 246 Results

### 247 Participant baseline characteristics

248 Using the NIH clinical guidelines for grading COVID-19 severity of 188 patients, 27 (14%)  
249 were asymptomatic, 75 (40%) were mild/moderate and 86 (46%) were severe cases.  
250 Collectively, the 188 patients contributed 400 blood samples collected over the first month of  
251 diagnosis: day 0 (187 samples), day 7 (50 samples), day 14 (53 samples), and day 28 (110  
252 samples). Fewer samples were collected on days 7 and 14 mainly due to design; that is,  
253 residual longitudinal plasma samples from AKUH biobank were only collected in day 0 and  
254 day 28. Of the 188 patients, 129 (69%) were male, 36 (19%) were from rural Kilifi and 152  
255 (81%) from urban Nairobi (Table 1). Their median age at recruitment was 48 years (IQR 37–  
256 58), with disease severity increasing with age. All 86 patients with severe COVID-19 were  
257 from Nairobi as we were unable to recruit severe patients in Kilifi. Underlying comorbidities  
258 such as diabetes, HIV/AIDS, and hypertension were prevalent among the mild/moderate and  
259 severe COVID-19 groups. Two participants with severe disease died on day 7 and 28  
260 respectively (Table 1).

261 **Table 1.** Participant demographic and clinical characteristics<sup>†</sup>

Characteristic	Asymptomatic (n = 27)	Mild/Moderate (n = 75)	Severe (n = 86)
Median age at recruitment (IQR), years	40 (33, 55)	46 (35, 54)	53 (43, 60)
Male sex	15 (56%)	46 (61%)	68 (79%)
Location			
Kilifi	21 (78%)	15 (20%)	0

Characteristic	Asymptomatic (n = 27)	Mild/Moderate (n = 75)	Severe (n = 86)
Nairobi	6 (22%)	60 (80%)	86 (100%)
<b>Comorbidities</b>			
Diabetic	1 (7%)	28 (42%)	47 (63%)
Hypertensive	0	15 (22%)	33 (44%)
HIV positive	0	5 (8%)	4 (5%)
Had COPD	0	0	1 (1%)
Had Renal disease	0	0	2 (3%)
Had heart disease	0	0	6 (8%)
<b>Patient management</b>			
Were hospital admissions	0	56 (84%)	75 (100%)
In intensive care unit	0	4 (6.0%)	15 (20%)
Clinical Outcome, died	0	0	2 (3%)

262 † Data are median (IQR) or number (%); COPD if Chronic obstructive pulmonary disease.

## 263 Kinetics and frequencies of *ex vivo* IFN- $\gamma$ secreting cells by

### 264 COVID-19 severity and geographical location

265 Kinetics and levels of IFN- $\gamma$  secreting cell responses were assessed in a subset of 59  
266 participants with PBMC samples, contributing 172 samples. At day 0, the frequency of IFN- $\gamma$   
267 secreting cells to overlapping SARS-CoV-2 spike peptide was significantly higher in  
268 asymptomatic patients compared to severe patients (GMs: 117 [95% CI 71–194] vs 32 [95%  
269 CI 8–76]; p=0.0366) (Figure 1a, Table S3). For the IFN- $\gamma$  secreting cells specific to

270 overlapping M peptides, severe patients exhibited significantly higher levels at day 7 than  
271 mild/moderate patients (GMs: 90 [95% CI 37–217] vs 19 [95% CI 10–39];  $p=0.0180$ ; Figure  
272 1b, Table S3). We did not observe any significant differences in the frequencies of IFN- $\gamma$   
273 secreting cell responses to NP, NSPs, and ORFs overlapping peptides (Figure 1c–e, Table  
274 S3). For all five SARS-CoV-2 peptides we observed temporal differences in IFN- $\gamma$  secreting  
275 cells within each COVID-19 severity group (Figure 1, Table S3). Spike peptide: In the  
276 asymptomatic group, IFN- $\gamma$  secreting cells were significantly elevated on day 7 than on day  
277 14 (GMs: 161 [95% CI 86–301] vs 92 [95% CI 44–189];  $p=0.0039$ ) and day 28 (102 [95% CI  
278 49–209];  $p=0.0042$ ). For the mild/moderate group, levels significantly increased from 86  
279 (95% CI 53–138) on day 7 to 142 (95% CI 78–257) on day 14 ( $p=0.0403$ ). In the severe  
280 group, significantly higher levels were observed on day 7 (70 [95% CI 29–165];  $p=0.0381$ ),  
281 day 14 (117 [95% CI 52–260];  $p=0.0058$ ), and day 28 (108 [95% CI 33–348];  $p=0.0037$ )  
282 relative to day 0 (23 95% CI 7–76).

283 M Peptide: In the asymptomatic patients, IFN- $\gamma$  secreting cells were significantly higher on  
284 day 14 (89 [95% CI 30–258]) compared to day 0 (GMs: 28 [95% CI 13–59];  $p=0.0364$ ) and  
285 day 7 (GMs: 48 [95% CI 18–129];  $p=0.0297$ ). In the mild/moderate group, day 14 levels  
286 were significantly higher compared to day 0 ( $p=0.0039$ ), day 7 ( $p<0.0001$ ), and day 28  
287 ( $p=0.002$ ). Additionally, day 28 levels were significantly higher than day 7 ( $p=0.0049$ ). No  
288 significant differences were observed between timepoints in the severe group.

289 NP Peptide: Among the asymptomatic group, a significant decline was observed from day 7  
290 (71 [95% CI 33–153]) to day 28 (47 [95% CI 24–88];  $p=0.0035$ ). In the mild/moderate  
291 group, IFN- $\gamma$  secreting cell levels were significantly higher on day 14 (GMs: 67 [95% CI 34–  
292 130]) compared to day 0 (GMs: 35 [95% CI 14–83];  $p=0.0037$ ), day 7 (GMs: 44 [95% CI 26–  
293 73];  $p=0.0178$ ), and day 28 (GMs: 47 [95% CI 24–91];  $p=0.0003$ ). No significant differences  
294 were observed between timepoints in the severe group. For NSP peptide: a significant decline

295 in IFN- $\gamma$  secreting cells was observed within the mild/moderate group from 80 (95% CI 33–  
296 194) at day 14 to 28 (95% CI 7–106) at day 28 ( $p=0.0316$ ). For ORF peptide: a significant  
297 increase in IFN- $\gamma$  secreting cells was observed in the mild/moderate group between day 0 (14  
298 [95% CI 4–43]) and day 7 (GMs: 38 [95% CI 16–85];  $p=0.0242$ ).

299 **Figure 1. Induction of a higher IFN-gamma cellular response to Spike protein on day of**  
300 **diagnosis is associated with asymptomatic infection.**

301 Frequencies of ex-vivo IFN- $\gamma$  secreting cells against SARS-CoV-2 peptide pools spanning (a)  
302 spike protein, (b) M protein, c NP protein, (d) NSP proteins and (e) ORF proteins. Bars  
303 represent geometric mean and 95% CI.

304 Linear mixed effects model with Tukey’s multiple comparisons, was used, \*  $P < 0.05$ .

305 Number of samples analysed for: spike responses = 171, M responses = 136, NP responses =  
306 162, NSP responses = 100 and ORF responses = 90.

307

308 We also assessed whether there were differences in IFN- $\gamma$  secreting cell responses by location  
309 (urban Nairobi and rural Kilifi) among asymptomatic and mild patients. Relative to Nairobi,  
310 significantly higher levels of IFN- $\gamma$  secreting cell responses to the SARS-CoV-2 spike  
311 peptide (218 [95% CI 125–381] vs 56 [95% CI 28–110];  $p=0.0057$ ; Figure 2a) and NP  
312 peptide (94 [95% CI 51–169] vs 19 [95% CI 8–48;  $p=0.0171$ ; Figure 2c) were observed  
313 among the asymptomatic patients in Kilifi on day 0. There were no significant differences  
314 between Kilifi and Nairobi in the IFN- $\gamma$  secreting cell responses to overlapping peptides for  
315 the M protein for the asymptomatic patients (Figure 2b), nor for the spike, or NP, and or M  
316 peptides among mild patients (Figure 2d–f). Data for severe patients are shown for Nairobi  
317 participants only (Figure 2g–i), as we were unable to recruit severe patients in Kilifi.

318 **Figure 2. Induction of a higher IFN- $\gamma$  cellular response on the day of diagnosis is**  
319 **associated with Kilifi participants.**

320 Comparison of IFN- $\gamma$  cellular responses between Kilifi and Nairobi COVID-19 patients with:  
321 asymptomatic disease for (a) Spike protein, (b) M protein, (c) NP protein; Mild disease for  
322 (d) Spike protein, (e) M protein, (f) NP protein; and Severe disease for (g) Spike protein, (h) M  
323 protein, (i) NP protein. Kilifi didn't have severe patients.  
324 Bars represent geometric mean and 95% CI. Kruskal–Wallis one-way ANOVA, with Dunn's  
325 multiple comparisons test, was performed. \*  $P < 0.05$ , \*\* $P < 0.01$ .

326

### 327 **Kinetics of cytokine and chemokine responses across COVID-19** 328 **severity groups and geographical location**

329 Asymptomatic patients consistently showed elevated levels of SDF-1 $\alpha$  at all time-points, but  
330 lower levels of all the other cytokines and chemokines measured and no detectable levels of  
331 IL-9 (Figure 3a). Similarly, for mild/moderate patients, high levels of SDF-1 $\alpha$  (Figure 3b),  
332 were observed at all timepoints whereas other cytokines and chemokines were secreted at low  
333 to intermediate levels. High cytokine and chemokines levels were seen among the severe  
334 patients with IL-1 $\beta$ , IL-6, IL-2, IFN- $\gamma$ , GM-CSF, IFN- $\alpha$ , IL-7 and GRO- $\alpha$  decreasing over  
335 time, while MIP-1 $\alpha$ , MIP-1 $\beta$ , MCP-1, and SDF-1 $\alpha$  increased with time. Levels for IL1-ra, and  
336 IL-9 were similar at all the time points (Figure 3c).

#### 337 **Figure 3. Kinetics of Cytokine and Chemokine Concentrations in COVID-19 Patients.**

338 Mean of log<sub>10</sub>-transformed cytokine/chemokine concentrations plotted over time for (a)  
339 Asymptomatic participants, (b) Mild/Moderate participants, and (c) Severe participants. \* -  
340 Levels for all participants were below detectable levels.

341

342 We compared asymptomatic against mild/moderate and severe participants to evaluate  
343 differences among the clinical phenotypes. Mild/moderate participants had significantly  
344 higher levels of IL-18, IL-8, IL-1ra, IL-6, GM-CSF, IP-10, MCP-1, TNF- $\alpha$ , MIP-1 $\alpha$ , IFN- $\gamma$ ,



345 IL-2, IL-7, IL-1 $\beta$ , IL-9, Eotaxin and IFN- $\alpha$  than asymptomatic patients. The largest effect  
346 sizes were observed with IL-18 (1.107,  $p < 0.0001$ ), IL-8 (1.105,  $p < 0.0001$ ) and IL-1ra,  
347 (0.672,  $p = 0.013$ ). On the contrary, levels for SDF-1 $\alpha$  were significantly reduced among the  
348 mild/moderate patients relative to the asymptomatic (effect size -0.182,  $p < 0.0001$ ) (Figure 4).  
349 Severe participants had significantly higher levels for cytokines (IL-8, IL-18, IL-1ra, IL-6,  
350 IP-10, MIP-1 $\alpha$ , TNF- $\alpha$ , IL-9, IFN- $\gamma$ , GM-CSF, IL-7, IL-1 $\beta$ , MCP-1, IL-2, GRO- $\alpha$ , Eotaxin  
351 and IFN- $\alpha$ ) compared to asymptomatic cases, except for IL-1a, IL-21 and MIP-1 $\beta$  which had  
352 similar levels, and SDF-1 $\alpha$  (effect size -0.195,  $p < 0.0001$ ), which was significantly reduced.  
353 The largest effect size was observed in IL-8 (1.754,  $p < 0.0001$ ), IL-18 (1.666,  $p < 0.0001$ ) and  
354 IL-1ra (1.197,  $p < 0.0001$ ) (Figure 4).  
355 For asymptomatic individuals, the cytokines and chemokine levels for IL-6, MIP-1 $\alpha$ , IL-18,  
356 GRO- $\alpha$ , IL-2, IL-8, TNF- $\alpha$  and GM-CSF were significantly higher among Nairobi than Kilifi  
357 patients. Comparisons for IL-6 (1.139,  $p < 0.0001$ ), MIP-1a (1.093,  $p = 0.004$ ) and IL-18  
358 (1.025,  $p = 0.002$ ) had the largest effect sizes (Figure 4). For mild patients, all cytokines (IL-8,  
359 IL-18, IL-1ra, MIP-1 $\alpha$ , IL-6, IP-10, IFN- $\gamma$ , TNF- $\alpha$ , MCP-1, GM-CSF, IL-9, IL-1 $\beta$ , Eotaxin,  
360 IL-7, MIP-1 $\beta$ , and IFN- $\alpha$ ) were significantly higher among Nairobi patients in comparison to  
361 Kilifi patients except for GRO- $\alpha$ , IL-1 $\alpha$ , IL-2 and IL-21 which were similar. Notably, the  
362 largest effect size for these comparisons was observed for IL-8 (1.69,  $p < 0.0001$ ), IL-18  
363 (1.634,  $p < 0.0001$ ) and IL-1ra (1.355,  $p < 0.001$ ). On the other hand, SDF-1 $\alpha$  (effect size -  
364 0.161,  $p = 0.017$ ) was significantly lower in Nairobi than in Kilifi patients.

365 **Figure 4. Higher Cytokine and Chemokine concentrations in Asymptomatic and Mild**  
366 **Patients from Nairobi Compared to Kilifi, and in Mild/Moderate and Severe Patients**  
367 **Compared to Asymptomatic Individuals.**

368 ns – not-significant,  $p$  value  $> 0.05$ , empty means it was significant at  $p < 0.05$  -  $< 0.0001$ . \* -  
369 Levels for all participants were below detectable levels.

370

371

## 372 **Principal component analysis**

373 The concentrations of the majority of the 21 cytokines and chemokines were positively  
374 correlated with each other. However, the levels of SDF-1 $\alpha$  were negatively correlated with  
375 those of IL-2, IP-10, IL-7, IFN- $\gamma$ , GM-CSF, and IL-18 (Figure S1). We retained the first three  
376 principal components from a principal component analysis, accounting for 62% of the total  
377 variability in the 21 cytokines and chemokines (Figure S2a). IL-9, MIP-1 $\alpha$ , TNF- $\alpha$ , MCP-1,  
378 MIP-1 $\beta$ , IL1-ra, IL-6, IL-1 $\beta$ , GRO- $\alpha$  and IL-8 were the most strongly associated with the first  
379 PC. The second PC was most strongly associated with IP-10, IFN- $\gamma$ , GM-CSF, IL-2, IL-18,  
380 IL-7, IFN- $\alpha$ , Eotaxin and SDF-1 $\alpha$ . The third PC was associated with IL-1  $\alpha$  and IL-21 (Figure  
381 S3). There was no clear separation among the mild/moderate and severe groups. However,  
382 data points for the asymptomatic participants clustered together demonstrating a much-  
383 reduced diversity of cytokine and chemokine levels than the other groups (Figure 5), and  
384 median PC scores did not change over the first month (Figure S2b).

### 385 **Figure 5. Scatter plot by Severity at baseline.**

386 **(a) PC1 vs PC2; (b) PC2 vs PC3**

387

388 Among the symptomatic groups (mild/moderate/severe), a steady decline of all the PCs over  
389 one month was observed, with a steep decline occurring between day 0 and day 7 (Figure  
390 S2c). There was no apparent difference of the cytokine and chemokine responses between  
391 asymptomatic participants from Kilifi and Nairobi (Figure S4a). For mild cases, Kilifi  
392 patients clustered together, although there was a slight overlap with Nairobi participants  
393 (Figure S4b). Using biplots, there was no apparent difference between asymptomatic and  
394 mild Kilifi patients (Figure S4c). For Nairobi, clinical phenotypes were asymptomatic, mild,  
395 moderate, and severe. We combined the mild and moderate, and observed no clear difference

396 between the mild/moderate and severe groups, while the few asymptomatic participants  
397 seemed to cluster together (Figure S4d).

398

399

400

## 401 **Discussion and conclusion**

402 In this study, we measured associations between the acute IFN- $\gamma$  cellular, and 22 cytokine  
403 and chemokine, immune response to SARS-CoV-2 (within a month of diagnosis) with  
404 COVID-19 severity and possible modulation by differential environmental exposures in  
405 urban and rural areas in Kenya.

406 As had been seen in earlier reports from Singapore, Netherlands, and Italy, which associated  
407 increased IFN- $\gamma$  secreting cells measured by ELISpot assay in the early phase of infection  
408 with milder disease (38–40), we found that higher frequencies of an early IFN- $\gamma$  cellular  
409 response to SARS-CoV-2 spike overlapping peptides was associated with asymptomatic,  
410 compared to severe SARS-CoV-2 infection outcomes. This observation would suggest either:  
411 1) that the IFN- $\gamma$  cellular response contribute to protection against disease progression, or 2)  
412 that developing severe COVID-19 depresses this response. The latter interpretation may be  
413 supported by previous reports from China and USA reporting correlations of an early  
414 induction of increased basal T-cell specific responses (CD4<sup>+</sup> and CD8<sup>+</sup> T) in COVID-19  
415 patients with mild disease, which was suppressed among their severely sick counterparts  
416 (41,42).

417 Whilst the concentrations of the pro-inflammatory cytokines and chemokines IL-6, IL-I $\beta$ ,  
418 GRO- $\alpha$ , IFN- $\gamma$ , GM-CSF, IFN- $\alpha$ , IL-7 and IL-2 in severe patients declined to basal levels at  
419 day 28 from day of diagnosis, we found that the concentrations for the chemokines MIP-1 $\alpha$ ,  
420 MIP-I $\beta$ , MCP-1, and SDF-1 $\alpha$  were increasing with time. This is to be expected as cytokines  
421 and chemokines play different roles and at different times of the immune response to  
422 infection. MIP-1 $\alpha$ , MCP-1 and MIP-I $\beta$  are chemoattractant and play key roles in the  
423 recruitments of leukocytes such as monocytes, T-cells, and neutrophil to the sites of infection  
424 (43,44). Similarly increasing kinetics for MIP-1 $\alpha$  and MCP-1 in severe and fatal patients  
425 were reported in Norway and China, respectively (45,46). Notably, we found that higher

426 concentrations of SDF-1 $\alpha$  were associated with asymptomatic individuals, hinting at a  
427 potential protective role from severe disease progression. SDF-1 $\alpha$  (CXCL12), is a  
428 chemokine involved in the recruitment of T-cells (47), CD34+ hematopoietic stem/progenitor  
429 cells (48), lymphocytes and monocytes (49) to the site of infection further enhancing  
430 inflammation. In contrast, studies from China and Bulgaria did not observe significant  
431 differences in SDF-1 $\alpha$  levels among asymptomatic, mild, moderate, severe or fatal cases  
432 (18,46,50). However, others have also implicated SDF-1 $\alpha$  in disease severity based on  
433 genetic association studies in a single-centre study (51), although this finding was not  
434 corroborated in multi-centre genome-wide association studies (52). SDF-1 $\alpha$  may aid in the  
435 timely recruitment of T and other cells (47), to the sites of infection, enhancing viral  
436 elimination, reduction in inflammation, and promotion of recovery.

437 We demonstrate that elevated levels of eighteen cytokines and chemokines were associated  
438 with severe COVID-19, in agreement with previous reports linking them to severe lung  
439 injury and ARDS (17–22,53). However, the associations with IL-8, IL-18 and IL-1ra, had the  
440 strongest effect sizes in the current study. IL-8, has been implicated in the activation and  
441 recruitment of neutrophils to the site of infection, thereby promoting inflammation (54). IL-  
442 18 amplifies the immune response by inducing the production of IFN- $\gamma$  by T-cells and natural  
443 killer cells (55). Thus, IL-8 and IL-18 could amplify the excessive inflammation that  
444 characterises severe COVID-19. On the contrary, IL1-ra is known to suppress the production  
445 of proinflammatory cytokines such as IL-1 and TNF- $\alpha$  (56), and probably helps mitigate the  
446 effects of excessive inflammation, thus reducing tissue damage and associated mortality.

447 In parallel to the reduced rates of severe COVID-19 and associated deaths in SSA relative to  
448 North America and Europe, we and others have suggested higher rates of severe COVID-19  
449 in cities compared to rural areas in SSA (28). Whilst this difference could be explained by  
450 higher levels of SARS-CoV-2 transmission in busy metropolitan cities, or by more complete

451 reporting of cases (28,57,58), we wondered whether there were also plausible biological  
452 explanations. We compared inflammatory cytokine and chemokine levels, and found that the  
453 asymptomatic patients from Nairobi had higher levels of 8 cytokines and chemokines than  
454 their asymptomatic counterparts from Kilifi, with IL-6, IL-18 and MIP-1 $\alpha$ , having the  
455 strongest associations. Similarly, levels of 16 cytokines and chemokines were higher among  
456 mild- Nairobi, than Kilifi, COVID-19 patients with IL-8, IL-18 and IL-1ra being the most  
457 differentially secreted. Moreover, the basal frequencies of IFN- $\gamma$  secreting cells in  
458 asymptomatic patients from Nairobi, relative to those of their Kilifi counterparts, were  
459 reduced. Collectively, these findings would suggest that the immune response to SARS-CoV-  
460 2 is less inflammatory among residents of rural areas (59).

461 Our study was faced with a few limitations. Firstly, our data are incomplete for some of the  
462 patients due to missed follow-ups, or due to unavailability of adequate numbers of PBMCs to  
463 quantify IFN- $\gamma$  cellular responses to the full spectrum of the peptide pools corresponding to  
464 all the different SARS-CoV-2 proteins. However, our analyses are assumed valid under the  
465 missing at random mechanism given the likelihood approach (60). Secondly, we had  
466 difficulties recruiting asymptomatic patients in Nairobi and were unable to recruit severe  
467 cases in Kilifi and thus the sample size is relatively small.

468 In conclusion, although severe disease was rare in Kenya, the inflammatory cytokine profile  
469 in patients with severe COVID is similar to that of North American and European severe  
470 COVID-19 patients. However, just like the early IFN- $\gamma$  secreting cellular response, increased  
471 levels of the chemokine, SDF-1 $\alpha$ , were associated with asymptomatic SARS-CoV-2  
472 infection, suggesting a potential role of these responses in protection against disease  
473 progression. Finally, the differential cytokine and chemokine, and IFN- $\gamma$  cellular responses  
474 between urban Nairobi and rural Kilifi patients suggest a plausible biological explanation for  
475 the increased frequency of severe COVID-19 in African SSA cities relative to rural areas.

476 Together, these findings provide insights into potentially COVID-19 protective immune  
477 responses, and their modulation by differential environmental exposures. Nonetheless,  
478 additional studies are required to extend and replicate these important findings as they could  
479 inform future control of COVID-19 and empower the control of similar pandemics.

480

481

## 482 **Acknowledgments**

483 We thank the field workers, laboratory staff and healthcare workers involved in the

484 longitudinal blood sampling. We appreciate all the study participants.

485



## 486 **References**

- 487 1. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al. COVID-  
488 19 in the 47 countries of the WHO African region: a modelling analysis of past trends and  
489 future patterns. *Lancet Glob Health*. 2022 Aug;10(8):e1099–114.
- 490 2. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science*.  
491 2021 Jan;371(6524):27–8.
- 492 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A  
493 Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-  
494 Vaccine Hypothesis to the Test. *Earth Syst Environ*. 2021 Sep 1;5(3):799–810.
- 495 4. Diop BZ, Ngom M, Poug ue Biyong C, Poug ue Biyong JN. The relatively young and rural  
496 population may limit the spread and severity of COVID-19 in Africa: a modelling study.  
497 *BMJ Glob Health*. 2020 May;5(5):e002699.
- 498 5. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What  
499 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of  
500 the SARS-CoV-2 Virus? *Int J Environ Res Public Health*. 2021 Aug 16;18(16):8638.
- 501 6. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al. Peptide  
502 microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from  
503 Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-  
504 sectional study. *Lancet Microbe*. 2023 Apr 1;4(4):e215–27.
- 505 7. Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-  
506 reactive T cells in healthy donors and patients with COVID-19. *Nature*. 2020 Nov  
507 12;587(7833):270–4.

- 508 8. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-  
509 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.  
510 Nature. 2020 Aug;584(7821):457–62.
- 511 9. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of  
512 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and  
513 Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15.
- 514 10. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.  
515 Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute  
516 respiratory distress syndrome. Sci Immunol. 2020 Jun 26;5(48):eabd2071.
- 517 11. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and  
518 cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct  
519 2;370(6512):89–94.
- 520 12. Naidoo P, Ghazi T, Chuturgoon AA, Naidoo RN, Ramsuran V, Mpaka-Mbatha MN,  
521 et al. SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: An  
522 epidemiological and immunological perspective. Environ Int. 2021 Nov 1;156:106695.
- 523 13. Anyanwu MU. The association between malaria prevalence and COVID-19 mortality.  
524 BMC Infect Dis. 2021 Sep 19;21(1):975.
- 525 14. Mogensen TH, Paludan SR. Virus-cell interactions: impact on cytokine production,  
526 immune evasion and tumor growth. Eur Cytokine Netw. 2001;12(3):382–90.
- 527 15. Mogensen TH, Paludan SR. Molecular Pathways in Virus-Induced Cytokine  
528 Production. Microbiol Mol Biol Rev. 2001 Mar;65(1):131.

- 529 16. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in  
530 COVID-19. *J Infect.* 2020 Jun;80(6):607–13.
- 531 17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
532 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet.* 2020 Feb  
533 15;395(10223):497–506.
- 534 18. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum Cytokine and Chemokine  
535 Profile in Relation to the Severity of Coronavirus Disease 2019 in China. *J Infect Dis.*  
536 2020 Aug 4;222(5):746–54.
- 537 19. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune  
538 Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect*  
539 *Dis Off Publ Infect Dis Soc Am.* 2020 Jul 28;71(15):762–8.
- 540 20. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.  
541 Patterns of cytokine and chemokine expression in peripheral blood of patients with  
542 COVID-19 associated with disease severity. *Int J Immunopathol Pharmacol.* 2023  
543 Dec;37:039463202311636.
- 544 21. Ndoricyimpaye EL, Van Snick J, Robert R, Bikorimana E, Majyambere O,  
545 Mukantwari E, et al. Cytokine Kinetics during Progression of COVID-19 in Rwanda  
546 Patients: Could IL-9/IFN $\gamma$  Ratio Predict Disease Severity? *Int J Mol Sci.* 2023 Jul  
547 31;24(15):12272.
- 548 22. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal Cytokine  
549 Profile in Patients With Mild to Critical COVID-19. *Front Immunol [Internet].* 2021 Dec 6  
550 [cited 2024 Apr 19];12. Available from:

- 551 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.763292/ful>
- 552 1
- 553 23. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
- 554 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
- 555 infected patients. *eBioMedicine* [Internet]. 2020 May 1 [cited 2024 Jul 18];55. Available
- 556 from: [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(20\)30138-](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30138-9/fulltext)
- 557 [9/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30138-9/fulltext)
- 558 24. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore
- 559 SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for
- 560 GM-CSF in severe COVID-19. *Sci Immunol*. 2021 Mar 10;6(57):eabg9873.
- 561 25. Darif D, Hammi I, Kihel A, Saik IEI, Guessous F, Akarid K. The pro-inflammatory
- 562 cytokines in COVID-19 pathogenesis: What goes wrong? *Microb Pathog*. 2021
- 563 Apr;153:104799.
- 564 26. Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, et al. Kinetics of naturally
- 565 induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among
- 566 SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an
- 567 observational study. *Wellcome Open Res*. 2023 Aug 17;8:350.
- 568 27. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021
- 569 Feb;184(4):861–80.
- 570 28. Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, et al. COVID-19
- 571 transmission dynamics underlying epidemic waves in Kenya. *Science*. 2021 Nov
- 572 19;374(6570):989–94.

- 573 29. NIH. COVID-19 Treatment Guidelines. 2021 [cited 2024 Jun 13]. Clinical Spectrum  
574 of SARS-CoV-2 Infection. Available from:  
575 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- 576 30. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and  
577 antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-  
578 CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet  
579 Microbe. 2022 Jan;3(1):e21–31.
- 580 31. Merck KGaA. Sigmaaldrich Belysa® Immunoassay Curve Fitting Software,  
581 Darmstadt, Germany. 2022 [cited 2024 Apr 11]. Belysa® Immunoassay Curve Fitting  
582 Software. Available from: [https://www.sigmaaldrich.com/KE/en/services/software-and-](https://www.sigmaaldrich.com/KE/en/services/software-and-digital-platforms/belysa-immunoassay-curve-fitting-software)  
583 [digital-platforms/belysa-immunoassay-curve-fitting-software](https://www.sigmaaldrich.com/KE/en/services/software-and-digital-platforms/belysa-immunoassay-curve-fitting-software)
- 584 32. Gelman A, Hill J. Higher Education from Cambridge University Press. Cambridge  
585 University Press; 2006 [cited 2024 Oct 28]. Data Analysis Using Regression and  
586 Multilevel/Hierarchical Models. Available from:  
587 [https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-](https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983)  
588 [multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983](https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983)
- 589 33. R Core Team. R Foundation for Statistical Computing, Vienna, Austria. 2023 [cited  
590 2024 Mar 8]. R: A language and environment for statistical computing. Available from:  
591 <https://www.R-project.org/>
- 592 34. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate  
593 Data Analyses [Internet]. 2020 [cited 2024 Mar 8]. Available from: [https://CRAN.R-](https://CRAN.R-project.org/package=factoextra)  
594 [project.org/package=factoextra](https://CRAN.R-project.org/package=factoextra)

- 595 35. Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2024 Mar 8]. (R package  
596 version 1.0.12). Available from: [https://cran.r-](https://cran.r-project.org/web/packages/pheatmap/index.html)  
597 [project.org/web/packages/pheatmap/index.html](https://cran.r-project.org/web/packages/pheatmap/index.html)
- 598 36. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Cham: Springer  
599 International Publishing, New York; 2016 [cited 2024 Mar 8]. (Use R!). Available from:  
600 <http://link.springer.com/10.1007/978-3-319-24277-4>
- 601 37. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.  
602 2023 [cited 2024 Apr 11]. Prism - GraphPad. Available from:  
603 <https://www.graphpad.com/features>
- 604 38. Tan AT, Linster M, Tan CW, Bert NL, Chia WN, Kunasegaran K, et al. Early  
605 induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance  
606 and mild disease in COVID-19 patients. Cell Rep [Internet]. 2021 Feb 9 [cited 2024 Aug  
607 3];34(6). Available from: [https://www.cell.com/cell-reports/abstract/S2211-](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00041-3)  
608 [1247\(21\)00041-3](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00041-3)
- 609 39. Rümke LW, Smit WL, Bossink A, Limonard GJM, Muilwijk D, Haas LEM, et al.  
610 Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19. Front  
611 Immunol [Internet]. 2023 Apr 17 [cited 2024 Sep 13];14. Available from:  
612 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/f](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/full)  
613 [ull](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/full)
- 614 40. Garofalo E, Biamonte F, Palmieri C, Battaglia AM, Sacco A, Biamonte E, et al.  
615 Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of  
616 IFN $\gamma$ -releasing cells: An exploratory study. PLOS ONE. 2023 Feb 9;18(2):e0281444.

- 617 41. Zeng Q, Li YZ, Dong SY, Chen ZT, Gao XY, Zhang H, et al. Dynamic SARS-CoV-  
618 2-Specific Immunity in Critically Ill Patients With Hypertension. *Front Immunol*  
619 [Internet]. 2020 Dec 10 [cited 2024 Sep 13];11. Available from:  
620 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596684/ful](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596684/full)  
621 1
- 622 42. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive  
623 features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. *Cell*  
624 *Rep* [Internet]. 2021 Jul 20 [cited 2024 Sep 13];36(3). Available from:  
625 [https://www.cell.com/cell-reports/abstract/S2211-1247\(21\)00827-5](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00827-5)
- 626 43. Takahashi M, Galligan C, Tessarollo L, Yoshimura T. Monocyte Chemoattractant  
627 Protein-1 (MCP-1), Not MCP-3, Is the Primary Chemokine Required for Monocyte  
628 Recruitment in Mouse Peritonitis Induced with Thioglycollate or Zymosan A. *J Immunol*  
629 *Baltim Md* 1950. 2009 Sep 1;183(5):3463–71.
- 630 44. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential Migration of  
631 Activated CD4<sup>+</sup> and CD8<sup>+</sup> T Cells in Response to MIP-1 $\alpha$  and MIP-1 $\beta$ . *Science*. 1993  
632 Apr 16;260(5106):355–8.
- 633 45. Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE,  
634 et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated  
635 with respiratory failure in COVID-19. *Sci Rep*. 2020 Dec 10;10:21697.
- 636 46. Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, et al. Temporal profiling of plasma  
637 cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients.  
638 *Signal Transduct Target Ther*. 2020 Jun 19;5(1):1–3.

- 639 47. Nanki T, Lipsky PE. Cutting Edge: Stromal Cell-Derived Factor-1 Is a Costimulator  
640 for CD4+ T Cell Activation. *J Immunol*. 2000 May 15;164(10):5010–4.
- 641 48. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The Chemokine SDF-1  
642 Is a Chemoattractant for Human CD34<sup>+</sup> Hematopoietic Progenitor Cells and Provides a  
643 New Mechanism to Explain the Mobilization of CD34<sup>+</sup> Progenitors to Peripheral Blood.
- 644 49. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly  
645 efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *J Exp*  
646 *Med*. 1996 Sep 1;184(3):1101–9.
- 647 50. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.  
648 Patterns of cytokine and chemokine expression in peripheral blood of patients with  
649 COVID-19 associated with disease severity. *Int J Immunopathol Pharmacol*. 2023  
650 Dec;37:039463202311636.
- 651 51. Korayem OH, Ahmed AE, Meabed MH, Magdy DM, Abdelghany WM. Genetic clues  
652 to COVID-19 severity: exploring the stromal cell-derived factor-1/CXCL12 rs2839693  
653 polymorphism in adult Egyptians. *BMC Infect Dis*. 2023 Oct 19;23:702.
- 654 52. Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, et al. GWAS  
655 and meta-analysis identifies 49 genetic variants underlying critical COVID-19. *Nature*.  
656 2023 May;617(7962):764–8.
- 657 53. Zhang Z, Ai G, Chen L, Liu S, Gong C, Zhu X, et al. Associations of immunological  
658 features with COVID-19 severity: a systematic review and meta-analysis. *BMC Infect Dis*.  
659 2021 Aug 3;21(1):738.



- 660 54. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential  
661 involvement of interleukin-8 (IL-8) in acute inflammation. *J Leukoc Biol.*  
662 1994;56(5):559–64.
- 663 55. Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding  
664 Protein. *Front Immunol* [Internet]. 2013 Oct 8 [cited 2024 Aug 21];4. Available from:  
665 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00289/full>
- 666 56. Dayer JM. Evidence for the biological modulation of IL-1 activity: The role of IL-  
667 1Ra. *Clin Exp Rheumatol.* 2001 Nov 30;20:S14-20.
- 668 57. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-  
669 CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second  
670 Waves of Infections, South Africa, July 2020–March 2021. *Emerg Infect Dis.* 2021  
671 Dec;27(12):3020–9.
- 672 58. Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of  
673 SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level  
674 of spread during the first wave of the pandemic. *EClinicalMedicine.* 2021 May  
675 1;35:100880.
- 676 59. Samandari T, Ongalo JB, McCarthy KD, Biegon RK, Madiega PA, Mithika A, et al.  
677 Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.  
678 *J Clin Invest.* 133(13):e170011.
- 679 60. Little RJA, Rubin DB. *Statistical Analysis with Missing Data.* John Wiley & Sons;  
680 2019. 462 p.
- 681

## 682 **Supporting information**

### 683 **Figure S1. Correlation matrix of 21 cytokines across all time points from 400 patients.**

684 Pearson's correlation coefficients are visualised, with red indicating positive correlations,  
685 blue negative correlations, and white representing no correlation.

686 **Figure S2. Principal component analysis of the cytokines. a)** Scree-plot showing that the  
687 first 3 principal components explained 62% of variability in the cytokines data for all  
688 participants; **(b)** Line plots for the first 3 principal component illustrating trends over time for  
689 asymptomatic participants; and **(c)** Line plots for the first 3 principal component illustrating  
690 trends over time for symptomatic (mild, moderate and severe) participants.

691 **Figure S3. Cytokines loading on the first three principal components (PC1–PC3).** The  
692 color scale indicates the loading value, with red indicating a higher positive loading, blue a  
693 higher negative loading and light-yellow minimal loading.

694 **Figure S4. Scatter plots showing cytokine data for participants grouped by location and**  
695 **clinical phenotype. (a)** Asymptomatic participants, **(b)** mild cases, **(c)** participants from  
696 Kilifi, and **(d)** participants from Nairobi. Each point represents an individual's cytokine  
697 measurement, allowing for a visual assessment of cytokine variability across different groups  
698 based on location and clinical presentation.

699 **Table S1. Peptides Sequences.** Each entry represents a distinct peptide along with its  
700 associated properties. The pooling strategy for the 10 peptide pools used is shown below.

701 **Table S2. Sample size for each peptide.** Number of participants sampled for each peptide  
702 across different clinical phenotypes (asymptomatic, mild/moderate, severe) and time points  
703 (Day 0, 7, 14, 28).

704 **Table S3. Associations of SARS-CoV-2 Peptides (Spike, M, NP, NSP, and ORF) with**  
705 **asymptomatic, mild/moderate, and severe clinical phenotypes over time.** Tukey's

706 multiple comparisons test was used to assess differences within and between clinical

707 phenotypes across different time points. Bold p values are significant,  $p < 0.05$ .

708




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5